Lamivudine treatment in patients with decompensated liver disease due to HBeAg negative chronic hepatitis B. A multicenter study.

被引：0
|
作者：
Manolakopoulos, S
Karatapanis, S
Elefsiniotis, J
Goulis, J
Mathou, N
Vlachogiannakos, J
Iliadou, E
Kougioumtzan, A
Economou, M
Tzourmakliotis, D
Avgerinos, A
机构：
[1] Polyclin Gen Hosp, Athens, Greece
[2] Gen Hosp Athens Elpis, Athens, Greece
[3] Elena Venizelou Hosp, Athens, Greece
[4] Evangelismos Gen Hosp, Athens, Greece
来源：
HEPATOLOGY | 2002年 / 36卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1930
引用
收藏
页码：645A / 645A
页数：1
相关论文
共 50 条
  • [31] A multicenter 3 year open study of lamivudine in HBeAg negative chronic hepatitis B (interim report of the first year).
    Tassopoulos, N
    Evgenidis, N
    Kitis, G
    Koutsounas, S
    Elefsiniotis, J
    Karatapanis, S
    Arvanitakis, K
    Vafiadis, I
    Kouroumalis, H
    Manolakopoulos, S
    Papaioannou, MG
    Vogiatzis, G
    HEPATOLOGY, 2001, 34 (04) : 323A - 323A
  • [32] Lamivudine treatment of chronic hepatitis B and post-liver transplant for fulminant hepatitis B.
    Proenza, J
    Friedenberg, F
    Rothstein, K
    Reich, D
    Manzarbeitia, C
    Munoz, S
    GASTROENTEROLOGY, 1997, 112 (04) : A1362 - A1362
  • [33] Entecavir versus lamivudine for HBeAg positive and negative chronic hepatitis B
    Lampertico, Pietro
    JOURNAL OF HEPATOLOGY, 2006, 45 (03) : 457 - 460
  • [34] Lamivudine vs lamivudine and interferon combination treatment of HBeAg(-) chronic hepatitis B
    Yurdaydin, C
    Bozkaya, H
    Çetinkaya, H
    Sahin, T
    Karaoguz, D
    Törüner, M
    Erkan, Ö
    Heper, AO
    Erden, E
    Bozdayi, AM
    Uzunalimoglu, Ö
    JOURNAL OF VIRAL HEPATITIS, 2005, 12 (03) : 262 - 268
  • [35] HBeAg negative patients with chronic hepatitis B are less likely to have a biochemical breakthrough during lamivudine treatment
    Akarca, US
    Gunsar, F
    Ersoz, G
    Ozacar, T
    Erensoy, S
    Akyildiz, M
    Kasap, E
    Akay, S
    Tekin, F
    Karasu, Z
    Batur, Y
    Ilter, T
    JOURNAL OF HEPATOLOGY, 2005, 42 : 170 - 170
  • [36] Treatment withdrawal after two years of lamivudine therapy in Chinese patients with HBeAg negative chronic hepatitis B
    Fung, S
    Wong, F
    Hussain, M
    Lok, AS
    HEPATOLOGY, 2002, 36 (04) : 637A - 637A
  • [37] Efficacy of the treatment of HBeAg-negative chronic hepatitis B patients with lamivudine: Results of 12 month therapy
    Seliverstova, T
    Isakov, V
    Bogomolov, P
    Mironova, O
    Pavlova, T
    Tsodikov, G
    Guschin, A
    HEPATOLOGY, 2002, 36 (04) : 637A - 637A
  • [38] A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation
    Fontana, RJ
    Hann, HWL
    Wright, T
    Everson, G
    Baker, A
    Schiff, ER
    Riely, C
    Anschuetz, G
    Riker-Hopkins, M
    Brown, N
    LIVER TRANSPLANTATION, 2001, 7 (06) : 504 - 510
  • [39] Lamivudine for patients with chronic hepatitis B and advanced liver disease
    Liaw, YF
    Sung, JJY
    Chow, WC
    Farrell, G
    Lee, CZ
    Yuen, H
    Tanwandee, T
    Tao, QM
    Shue, K
    Keene, ON
    Dixon, JS
    Gray, DF
    Sabbat, J
    NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (15): : 1521 - 1531
  • [40] CLEVUDINE WAS SUPERIOR TO LAMIVUDINE IN THE PATIENTS WITH HBEAG(+) CHRONIC HEPATITIS B
    Lau, George K.
    Leung, Nancy
    Hui, C. K.
    Kwok, A.
    Wong, A.
    Chan, R.
    Yoo, H. W.
    HEPATOLOGY, 2008, 48 (04) : 714A - 715A
12345